OOIR: Observatory of International Research

Papers

(The H4-Index of Antiviral Research is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination	114
Editorial Board	94
Editorial Board	78
Editorial Board	73
Corrigendum to “Crystal structure and cap binding analysis of the methyltransferase of langat virus” [Antivir. Res. 208 (2022) 105459]	69
Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs	55
Editorial Board	53
Hepatitis C virus elimination: So close, so far?	52
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies	50
Targeted inhibition of IGF2BP1 effectively suppresses HBV replication via an m6A-dependent manner	49
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier	45
ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection	43
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.	41
Novel inhibitors of HSV-1 protease effective in vitro and in vivo	41
Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models	41
Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants	41
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study	41
Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection	38
Understanding HBV immunopathogenesis to inform future immune-based therapies	38
Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients	37
Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections	37
Chemical-induced degradation of PreS2 mutant surface antigen via the induction of microautophagy	37
Editorial Board	36
Conserved use of the sodium/bile acid cotransporter (NTCP) as an entry receptor by hepatitis B virus and domestic cat hepadnavirus	36
Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response	36

Berberine promotes K48-linked polyubiquitination of HNF4α, leading to the inhibition of HBV replication	34
Structural and quantitative comparison of viral infection-associated N-glycans in plasma from humans, pigs, and chickens: Greater similarity between humans and chickens than pigs	33
Corrigendum to “Overview of gene editing strategies against HBV” [Antivir. Res. 247 (2026) 106355]	30
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals	30
Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses	30